ND Biosciences’ publishes a new paper in collaboration with the EPFL and ADX NeuroScience describing thorough characterization of 3 ELISA immunoassays that are most commonly used in clinical studies, demonstrating that these assays do not accurately measure the diversity and complexity of alpha-synuclein (aSYN) species in biological fluids. The d
ND Biosciences publishes a new paper demonstrating that the most commonly used alpha-synuclein (aSYN) ELISA assays don’t accurately measure the diversity and complexity of aSYN species in biological fluids.
ND Biosciences awarded a grant from The Michael J. Fox Foundation to accelerate the development of its assays for early diagnosis of Parkinson’s disease and monitoring disease progression
ND Biosciences awarded a grant from The Michael J. Fox Foundation to accelerate the development of its assays for early diagnosis of Parkinson’s disease and monitoring disease progression ND Biosciences announced today that it was awarded a grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate its diagnostics rese
ND Biosciences announces partnership with The Michael J. Fox Foundation for Parkinson’s Research to make available unique Synuclein proteoforms to the scientific community
ND-BioSciences Announces partnership with The Michael J. Fox Foundation for parkinson’s research to make available unique synuclein proteoforms to the scientific community Given ND Biosciences’ commitment to deploy its expertise, technical capabilities and integrated platforms to accelerate the discovery and validation of novel targets and
ND Biosciences awarded a grant from The Michael J. Fox Foundation to develop more accurate assays for early diagnosis of Parkinson’s disease and differentiating Parkinson’s disease from other neurodegenerative diseases
ND BioSciences, a Swiss-based biotechnology company that was
Check out the interview of our co-founder Bilal Fares with Sejelas, where he discusses ND Biosciences’ evolution, scientific innovation, and the realities of managing a biotech startup.
ND BioSciences, the Swiss biotech co-founded by Prof. Hilal Lashuel, the director of the laboratory of molecular and chemical biology
ND Biosciences est la sixième entreprise à rejoindre le StartLab
La start-up qui veut combattre les maladies neurodégénératives par des traitements novateurs
The Epfl Spin-Off ND Biosciences Receives Chf 100’000 To Fight Neurodegenerative Diseases
The biotech start-up based at Biopôle is developing innovative technologies for early diagnostics and therapies
ND Biosciences’ founders publish a systematic and critical review of Parkinson’s disease models
The development of disease models that recapitulate the key pathological and clinical features of neurodegenerative diseases
Award winning ND Biosciences joins StartLab
ND BioSciences, the Swiss biotech co-founded by Prof. Hilal Lashuel, the director of the laboratory of molecular and chemical biology
ND Biosciences awarded a new grant from The Michael J. Fox Foundation to develop more accurate and sensitive assays for quantifying α-Synuclein
ND BioSciences, a Swiss-based biotechnology company that was